Tag Archives: Jeffrey Ubben

Spinoff Odds & Ends: A Look At Shareholder Activism And Media Spin-offs(BIVV CSX TIME PSO TWX)

By |
8 Comments

It’s hump day. Here are some links to help you get through it: Marketfolly published some notes on a panel titled ‘The Future of Shareholder Activism’ at the Reuters Live Newsmaker Event. The panel featured some currently ‘active’ managers including ValueAct’s Jeffrey Ubben, Mantle Ridge’s Paul Hilal, Blackrock’s Zach Oleksiuk and Cadwalader’s Richard Brand (lawyer). Mr. Ubben has been… Read More »

Bioverativ(BIVV) Proves Attractive To Former Valeant(VRX) Patron ValueAct Capital

By |
5 Comments
bioverativ logo

Even before Biogen(BIIB) completed its spinoff of Bioverativ(BIVV), ValueAct Capital began buying “when-issued” stock in the new company. The hedge fund has continued to buy both stock and forward contracts and has now accumulated a 7.1% position in Bioverativ. The shares were purchased at between $40 and $45 per share. As Bioverativ stock has now risen above $50,… Read More »